Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The investigators propose to determine the engraftment and transplant related morbidity and
mortality after a non-myeloablative allogeneic hematopoietic stem cell transplant protocol
using immune- suppressive agents and low-dose total body irradiation (TBI) without standard
chemotherapy in patients with aggressive sickle cell disease who are not candidates for or
experienced complications from hydroxyurea therapy.
Fully HLA matched siblings will be used as donors for hematopoietic stem cells to reduce the
risk of morbidity and mortality in this cohort of patients.